<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        273-212-11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOX 500MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        67.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&minus; Pharmacotherapeutic group: </strong></p><p><strong>Levox </strong>tablets contain a medicine called levofloxacin, used in adults 18 years or older.</p><p>This belongs to a group of medicines called antibiotics. Levofloxacin is a &lsquo;quinolone&rsquo; antibiotic.</p><p>It works by killing the bacteria that cause infections in your body.</p><p>&nbsp;</p><p><strong>&minus; Therapeutic indications</strong>:</p><p><strong>Levox </strong>tablets can be used to treat infections of the:</p><p>&bull; Nasal sinuses.</p><p>&bull; Lungs, in people with long-term breathing problems or pneumonia.</p><p>&bull; Urinary tract, including your kidneys or bladder.</p><p>&bull; Prostate gland, where you have a long lasting infection.</p><p>&bull; Skin and underneath the skin, including muscles.</p><p>This is sometimes called &lsquo;soft tissue&rsquo;. Sometimes infections are caused by viruses rather than by bacteria. Examples include viral infections in the sinuses and lungs, such as the common cold or flu. Antibiotics, including Levox, do not kill viruses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a. Do not take this medicine and tell your doctor if:&nbsp;</strong><br />&bull; You are allergic to levofloxacin, any other quinolone antibiotic such as moxifloxacin,&nbsp;<br />ciprofloxacin or ofloxacin or any of the other ingredients of Levox tablets (listed in Section 6&nbsp;<br />below). Signs of an allergic reaction include rash, swallowing or breathing problems, and&nbsp;<br />swelling of your lips, face, throat or tongue.&nbsp;<br />&bull; You have ever had epilepsy.&nbsp;<br />&bull; You have ever had a problem with your tendons such as tendonitis that was related to&nbsp;<br />treatment with a &lsquo;quinolone antibiotic&rsquo;. &nbsp;</p><p>&bull; You are a child or a growing teenager.&nbsp;<br />&bull; You are pregnant, might become pregnant or think you may be pregnant.&nbsp;<br />&bull; You are breast-feeding.&nbsp;<br />Do not take this medicine if any of the above applies to you. If you are not sure, talk to your&nbsp;<br />doctor or pharmacist before taking Levox tablets.&nbsp;<br />Due to possible side effects, Levox is not recommended for pediatric and adolescent patients -<br />less than 18- except for the prevention of anthrax for those who are 6 months and older and&nbsp;<br />have breathed the anthrax bacteria germ.&nbsp;<br /><strong>Warning</strong>:&nbsp;<br /><strong>Tendon rupture or swelling of the tendon (tendinitis):&nbsp;</strong><br />- Tendons are the tough cords of tissue that connect muscles to bones. &nbsp;Pain, swelling, tears,&nbsp;<br />and inflammation of tendons including the back of the ankle (Achilles), shoulder, hand, or&nbsp;<br />other tendon sites can happen in people of all ages who take quinolone antibiotics, including&nbsp;<br />Levox. The risk of getting tendon problems is higher if you: &nbsp;<br />&bull; Are over 60 years of age. &nbsp;<br />&bull; Are taking steroids (corticosteroids). &nbsp;<br />&bull; Have had a kidney, heart or lung transplant. &nbsp;<br />&bull; Swelling of the tendon (tendinitis) and tendon rupture (breakage) have also happened in&nbsp;<br />patients who take quinolones who do not have the above risk factors. &nbsp;<br />&bull; Other reasons for tendon ruptures can include: &nbsp;<br />- Physical activity or exercise. &nbsp;<br />- Kidney failure. &nbsp;<br />- Tendon problems in the past, such as in people with rheumatoid arthritis (RA). &nbsp;<br />&bull; Call your doctor right away at the first sign of tendon pain, swelling or inflammation. Stop&nbsp;<br />taking Levox until tendinitis or tendon rupture has been ruled out by your healthcare provider.&nbsp;<br />Avoid exercise and using the affected area. The most common area of pain and swelling is the&nbsp;<br />Achilles tendon at the back of your ankle. This can also happen with other tendons. &nbsp;<br />&bull; Get medical help right away if you get any of the following signs or symptoms of a tendon&nbsp;<br />rupture: &nbsp;<br />- Hear or feel a snap or pop in a tendon area. &nbsp;<br />- Bruising right after an injury in a tendon area.&nbsp;<br />- Unable to move the affected area or bear weight. &nbsp;<br /><strong>b. Take special care with Levox.&nbsp;</strong><br /><strong>Check with your doctor or pharmacist before taking your medicine if you:&nbsp;</strong><br />&bull; Are 60 years of age or older.&nbsp;<br />&bull; Are using corticosteroids.&nbsp;<br />&bull; Have ever had a fit (seizure).&nbsp;<br />&bull; Have tendon problems. &nbsp;<br />&bull; Have low blood potassium (hypokalemia). &nbsp;<br />&bull; Have had damage to your brain due to a stroke or other brain injury.&nbsp;<br />&bull; Have kidney problems.&nbsp;<br />&bull; Have something known as &lsquo;glucose &ndash; 6 &ndash; phosphate dehydrogenase deficiency&rsquo;. &nbsp;<br />&bull; Have ever had mental health problems.&nbsp;<br />&bull; Have ever had heart problems.&nbsp;</p><p>&bull; Are diabetic.&nbsp;<br />&bull; Have bone and joint problems such as rheumatoid arthritis (RA) or other history of joint&nbsp;<br />problems.&nbsp;<br />&bull; Have nerve problems. &nbsp;<br />&bull; Have or anyone in your family has an irregular heartbeat, especially a condition called &ldquo;QT&nbsp;<br />prolongation&rdquo;. &nbsp;<br />&bull; Have ever had liver problems. &nbsp;<br />If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before&nbsp;<br />taking Levox tablets.&nbsp;<br /><strong>c. Using other medicines, herbal or dietary supplements:&nbsp;</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other&nbsp;<br />medicines. Do not start a new medicine without first consulting a doctor or pharmacist.&nbsp;<br />This includes medicines you buy without prescription, including herbal medicines. This is&nbsp;<br />because Levox tablets can affect the way some other medicines work. In addition, some&nbsp;<br />medicines can affect the way Levox tablets work.&nbsp;<br />In particular, tell your doctor if you are taking any of the following medicines. This is because&nbsp;<br />it can increase the chance of you getting side effects, when taken with Levox tablets:&nbsp;<br />&bull; <strong>Corticosteroids</strong>: used for inflammation. You may be more likely to have inflammation and/or&nbsp;<br />breakage of your tendons.&nbsp;<br />&bull; <strong>Warfarin</strong>: used to thin the blood. You may be more likely to have a bleed. Your doctor may&nbsp;<br />need to take regular blood tests to check how well your blood can clot.&nbsp;<br />&bull; <strong>Theophylline</strong>: used for breathing problems. You are more likely to have a fit (seizure) if taken&nbsp;<br />with Levox tablets.&nbsp;<br /><strong>&bull; Non-steroidal anti-inflammatory drugs (NSAIDS)</strong>: used for pain and inflammation such as&nbsp;<br />aspirin, ibuprofen, fenbufen, ketoprofen and indomethacin. You are more likely to have a fit&nbsp;<br />(seizure) if taken with Levox tablets.&nbsp;<br />&bull; <strong>Ciclosporin</strong>: used after organ transplants. You may be more likely to get the side effects of&nbsp;<br />Ciclosporin.&nbsp;<br />&bull;<strong> Medicines known to affect the way your heart beats:</strong> This includes medicines used for&nbsp;<br />abnormal heart rhythm (antiarrhythmics such as quinidine and amiodarone).&nbsp;<br /><strong>&bull; Tricyclic antidepressants:</strong> such as amitriptyline and imipramine. &nbsp;<br />&bull; <strong>Macrolide antibiotics</strong>: such as erythromycin,azithromycin and Clarithromycin.&nbsp;<br />&bull; <strong>Any oral anti-diabetes medicine or insulin.&nbsp;</strong><br /><strong>&bull; Anti-psychotic medicines. &nbsp;</strong><br />&bull;<strong> A water pill (</strong>diuretic). &nbsp;<br />&bull;<strong> Probenecid</strong>: (used for gout).&nbsp;<br /><strong>&bull; Cimetidine</strong>: used for ulcers and heartburn. &nbsp;<br />Special care should be taken when taking either of these medicines with Levox. &nbsp;<br />If you have kidney problems, your doctor may want to give you a lower dose.&nbsp;<br /><strong>Do not take Levox tablets at the same time as the following medicines. Either 2 hours&nbsp;<br />before or 2 hours after taking these products: &nbsp;</strong><br />&bull; Iron tablets (for anemia), multivitamin, or other product that has magnesium, aluminum, iron&nbsp;<br />or zinc. &nbsp;<br />&bull; Magnesium or aluminum-containing antacids (for acid or heartburn). &nbsp;</p><p>&bull; Sulcralfate (for stomach ulcers). &nbsp;<br />&bull; Didanosine antiviral drug for HIV.&nbsp;<br />This is because it can affect the way Levox tablets work.&nbsp;<br />Urine tests for opiates:&nbsp;<br />Urine tests may show &ldquo;false-positive&rdquo; results for strong painkillers called &ldquo;opiates&rdquo; in people&nbsp;<br />taking Levox ( levofloxacin) tablets. If your doctor is due to take a urine test, tell him you are&nbsp;<br />taking Levox tablets.&nbsp;<br /><strong>d. Pregnancy and breast-feeding:&nbsp;</strong><br />Do not take this medicine if:&nbsp;<br />&bull; You are pregnant, might become pregnant or think you may be pregnant.&nbsp;<br />&bull; You are breast-feeding or planning to breast-feed. &nbsp;<br />Ask your doctor or pharmacist for advice before taking any medicine if you are pregnant or&nbsp;<br />breast-feeding.&nbsp;<br /><strong>e. Driving and using machines:&nbsp;</strong><br />You may get side effects after taking this medicine, including feeling dizzy, sleepy, a spinning&nbsp;<br />feeling (vertigo) or changes to your eyesight. Some of these side effects can affect you being&nbsp;<br />able to concentrate and your reaction speed. If this happens, do not drive or carry out any work&nbsp;<br />that requires a high level of attention.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Levox tablets exactly as your doctor has told you. &nbsp;<br />&bull; Take this medicine by mouth.&nbsp;<br />&bull; Swallow the tablets whole with a drink of water.&nbsp;<br />&bull; The tablets may be taken during meals or at any time between meals.&nbsp;<br />&bull; Your doctor will decide on how many Levox tablets you should take.&nbsp;<br />&bull; The dose will depend on the type of infection you have and where the infection is in your&nbsp;<br />body.&nbsp;<br />&bull; The length of your treatment will depend on how serious your infection is.&nbsp;<br /><strong>Adults and the elderly with normal renal function:&nbsp;<br />Acute Bacterial Sinuses:&nbsp;</strong><br />&bull; 500 mg , once each day for 10-14 days.&nbsp;<br />&bull; 750 mg , once each day for 5 days.&nbsp;<br /><strong>Pneumonia:&nbsp;<br />Nosocomial Pneumonia:&nbsp;</strong><br />&bull; 750 mg, once each day for 7-14 days.&nbsp;<br /><strong>Community Acquired Pneumonia:&nbsp;</strong><br />&bull; 500 mg , once each day for 10-14 days. &nbsp;<br />&bull; 750 mg , once each day for 5 days.&nbsp;<br /><strong>Acute bacterial exacerbation of chronic bronchitis:&nbsp;</strong><br />&bull; 500 mg , once each day for 7 days.&nbsp;<br /><strong>Complicated urinary tract infection or acute pyelonephritis:&nbsp;</strong><br />&bull; 750 mg, each day for 5 days.&nbsp;<br />&bull; 250 mg, each day for 10 days.&nbsp;<br /><strong>Uncomplicated urinary tract infection:&nbsp;</strong><br />&bull; 250 mg, each day for 3 days.&nbsp;</p><p><strong>Chronic bacterial Prostatitis:&nbsp;</strong><br />&bull; 500 mg, once each day for 28 days.&nbsp;<br /><strong>Complicated skin and skin structure infections (SSSI):&nbsp;</strong><br />&bull; 750 mg, once each day for 7-14 days.&nbsp;<br /><strong>Uncomplicated (SSSI):&nbsp;</strong><br />&bull; 500 mg, once each day for 7-10 days. &nbsp;<br /><strong>Adults with kidney problems:&nbsp;</strong><br />Your doctor may need to give you a lower dose.&nbsp;<br /><strong>Children and Teenagers:&nbsp;</strong><br />This medicine must not be given to children or teenagers below 18 years.&nbsp;<br />Children have a higher chance of getting bone, joint, or tendon problems such as pain or&nbsp;<br />swelling while taking levofloxacin.&nbsp;<br /><strong>If you have been prescribed Levox after being exposed to anthrax:&nbsp;</strong><br />The Dose:&nbsp;<br />&bull; 500 mg, once each day for 60 days for adults and for children 6 months and older and their&nbsp;<br />weight is more than 50 kg.&nbsp;<br />Levox has been approved to lessen the chance of getting anthrax disease or worsening of the&nbsp;<br />disease after you are exposed to the anthrax bacteria germ. &nbsp;<br />Take Levox exactly as prescribed by your healthcare provider. Do not stop taking Levox&nbsp;<br />without talking with your healthcare provider. If you stop taking Levox too soon, it may not&nbsp;<br />prevent you from getting the anthrax disease. &nbsp;<br />It is not known if it is safe to use Levox for more than 28 days in adults and for more than 14&nbsp;<br />days in children 6 months of age and older. &nbsp;<br />If you are pregnant, or plan to become pregnant while taking Levox, you and your healthcare&nbsp;<br />provider should decide whether the benefits of taking Levox for anthrax are more important&nbsp;<br />than the risks. &nbsp;<br />In children 6 months and older who have breathed the anthrax bacteria germ: &nbsp;<br />&bull; Levox is used to prevent anthrax disease (inhalation anthrax). &nbsp;<br />&bull; It is not known if Levox is safe and works in children under the age of 6 months. &nbsp;<br /><strong>A. If you take more Levox tablets than you should:&nbsp;</strong><br />If you accidentally take more tablets than you should, tell a doctor or get other medical advice&nbsp;<br />straight away. Take the medicine pack with you. This is so the doctor knows what you have&nbsp;<br />taken. The following effects may happen:&nbsp;<br />Convulsive fits (seizures), feeling confused, dizzy, less conscious and heart problems leading&nbsp;<br />to uneven heart beats as well as feeling sick (nausea).&nbsp;<br /><strong>B. If you forget to take Levox tablets:&nbsp;</strong><br />If you forgot to take a dose, take it as soon as you remember unless it is nearly time for your&nbsp;<br />next dose. Do not double-up the next dose to make up for the missed dose.&nbsp;<br /><strong>C. If you stop taking Levox tablets:&nbsp;</strong><br />Do not stop taking Levox tablets just because you feel better. It is important that you complete&nbsp;<br />the course of tablets that your doctor has prescribed for you. If you stop taking the tablets too&nbsp;<br />soon, the infection may return, your condition may get worse or the bacteria may become&nbsp;<br />resistant to the medicine.&nbsp;<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Levox can cause side effects, although not everybody gets them. These&nbsp;<br />effects are normally mild or moderate and often disappear after a short time.&nbsp;<br /><strong>Stop taking Levox tablets and see a doctor straight away if you notice the following side effect:&nbsp;</strong><br /><strong>Very rare </strong>(affects less than 1 person in 10,000):<strong>&nbsp;</strong><br />&bull; You have an allergic reaction. Even after only one dose. The signs may include a rash,&nbsp;<br />swallowing or breathing problems, hives, hoarseness, rapid heart beat, faint, and swelling of&nbsp;<br />your lips, face, throat, or tongue.&nbsp;<br />&bull; Burning, tingling, pain, weakness and numbness in your arms, hands, legs or feet. These may&nbsp;<br />be signs of something called &lsquo;peripheral neuropathy&rsquo;. &nbsp;See a doctor straight away if you notice&nbsp;<br />any of these side effects. &nbsp;<br /><strong>Rare </strong>(affects less than 1 person in 1000):&nbsp;<br />&bull;<strong> Intestine infection </strong>(Pseudomembranous colitis): &nbsp;<br />Watery diarrhea, diarrhea that does not go away or which may have blood in it, possibly with&nbsp;<br />stomach cramps and a high temperature. These could be signs of a severe bowel problem.&nbsp;<br />&bull; Pain and inflammation in your tendons. The Achilles tendon is affected most often and in&nbsp;<br />some cases, the tendon could break.&nbsp;<br />&bull; Fits (convulsions).&nbsp;<br /><strong>Other</strong>:&nbsp;<br />&bull; Severe skin rashes that may include blistering or peeling of the skin around your lips, eyes,&nbsp;<br />mouth, nose and genitals.&nbsp;<br />&bull; Loss of appetite, skin and eyes becoming yellow in colour, dark-coloured urine, itching, or&nbsp;<br />tender stomach (abdomen). These may be signs of liver problems.&nbsp;<br /><strong>Tell your doctor if any of the following side effects gets serious or lasts longer than a few&nbsp;<br />days:</strong>&nbsp;<br /><strong>Common </strong>(affects less than 1 person in 10):&nbsp;<br />&bull; Feeling sick (nausea) and diarrhea.&nbsp;<br />&bull; Increase in the level of some liver enzymes in your blood.&nbsp;<br />&bull; Headache, feeling dizzy.&nbsp;<br />&bull; Insomnia.&nbsp;<br /><strong>Uncommon </strong>(affects less than 1 person in 100):&nbsp;<br />&bull; Itching and skin rash.&nbsp;<br />&bull; Loss of appetite, stomach upset or indigestion (dyspepsia), being sick (vomiting) or pain in&nbsp;<br />your stomach area, feeling bloated (flatulence) or constipation.&nbsp;<br />&bull; A spinning feeling (vertigo), feeling sleepy, sleeping problems or feeling nervous.&nbsp;<br />&bull; General weakness.&nbsp;<br /><strong>Rare </strong>(affects less than 1 person in 1,000):&nbsp;<br />&bull; Tingly feeling in your hands and feet (paraesthesia) or trembling.&nbsp;<br />&bull; Feeling stressed (anxiety), depressed, mental problems, feeling restless (agitation) or feeling&nbsp;<br />confused.&nbsp;<br />&bull; Unusual fast beating of your heart or low blood pressure.&nbsp;<br />&bull; Joint pain or muscle pain.&nbsp;<br />&bull; Bruising and bleeding easily due to a lowering in the number of blood platelets.&nbsp;<br />&bull; Low number of white blood cells (called neutropenia).&nbsp;</p><p>&bull; Difficulty breathing or wheezing (bronchospasm).&nbsp;<br />&bull; Severe itching or hives (called urticaria).&nbsp;<br /><strong>Very rare</strong> (affects less than 1 person in 10,000):&nbsp;<br />&bull; Increased sensitivity of your skin to sun and ultraviolet light.&nbsp;<br />&bull; Low blood sugar levels (hypoglycemia) and high blood sugar (hyperglycemia). This is&nbsp;<br />important for people that have diabetes.&nbsp;<br />&bull; Problems with your hearing or eyesight or changes in the way things taste and smell.&nbsp;<br />&bull; Seeing or hearing things that are not there (hallucinations), change in your opinion and&nbsp;<br />thoughts (psychotic reactions) with a chance of having suicidal thoughts.&nbsp;<br />&bull; Loss of circulation (anaphylactic like shock).&nbsp;<br />&bull; Muscle weakness. This is important in people with myasthenia gravis (a rare disease of the&nbsp;<br />nervous system). &nbsp;<br />&bull; Inflammation of the liver, changes in the way your kidney works and occasional kidney&nbsp;<br />failure which may be due to an allergic kidney reaction called interstitial nephritis.&nbsp;<br />&bull; Fever, sore throat and a general feeling of being unwell that does not go away. This may be&nbsp;<br />due to a lowering in the number of white blood cells.&nbsp;<br />&bull; Fever and allergic lung reactions.&nbsp;<br /><strong>Other side effects include:&nbsp;</strong><br />&bull; Lowering in red blood cells (anemia). This can make the skin pale or yellow due to damage&nbsp;<br />of the red blood cells and lowering in the number of all types of blood cells.&nbsp;<br />&bull; Exaggerated immune response (hypersensitivity).&nbsp;<br />&bull; Sweating too much (hyperhidrosis).&nbsp;<br />&bull; Pain, including pain in the back, chest and extremities.&nbsp;<br />&bull; Problems moving and walking.&nbsp;<br />&bull; Attacks of porphyria in people who already have porphyria.&nbsp;<br />&bull; Inflammation of your tubes that carry blood around your body (vessels) due to an allergic&nbsp;<br />reaction.&nbsp;<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,&nbsp;<br />please tell your doctor or pharmacist.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&minus; Keep out of the reach and sight of children.</p><p>&minus; Store below 30&deg;C, Store in the original carton.</p><p>&minus; Do not use Levox after the expiry date which is stated on the carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. What Levox contains: The active substance is levofloxacin. Each tablet of Levox 250 mg tablets contains 250 mg of levofloxacin, each tablet of Levox 500 mg tablets contains 500 mg of levofloxacin and each tablet of Levox 750 mg tablets contains 750 mg of levofloxacin. Excipients for core: Hydroxypropyl methylcellulose EP, crospovidone NF, silicified microcrystalline cellulose, and magnesium stearate.Excipients for film coating: Polysorbate 80 EP, titanium dioxide EP, purified talc EP, polyethylene glycol MW 6000 EP, hydroxypropyl methylcellulose EP, iron oxide yellow.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Levox tablets are film-coated tablets for oral use. The tablets are oblong with light yellow colour. 
Levox 250, 500, and 750 mg are available in pack sizes of 5 tablets. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by <strong>SPIMACO</strong></p><p>AlQassim pharmaceutical plant,</p><p>Saudi Arabia.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in June 2011. 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>المجموعة العلاجية الدوائية التي ينتمي إليها:</strong></p><p>تحتوي أقراص ليفوكس على دواء يسمى ليفوفلوكساسين والذي يستخدم في علاج المرضى من عمر 18 عاما فأكثر. وتنتمي مادة ليفوفلوكساسين لإحدى مجموعات المضادات الحيوية والتي تسمى الكوينولونات. وتعمل مادة ليفوفلوكساسين على قتل البكتيريا التي تسبب الأمراض المعدية في جسمك.</p><p><strong>الدواعي العلاجية:</strong></p><p><strong>تستخدم أقراص ليفوكس في علاج الأمراض المعدية التي تصيب:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجيوب الأنفية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرئتين وذلك في الأفراد الذين يعانون من مشاكل تنفسية طويلة الأمد أو الذين يعانون من الالتهاب الرئوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجهاز البولي ويشمل الكلى والمثانة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غدة البروستاتا وذلك في حالة حدوث العدوى طويلة الأمد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلد والأنسجة تحت الجلد والتي تشمل العضلات. وتسمى أيضا الأنسجة تحت الجلد &quot;بالأنسجة الرخوة&quot;.</p><p dir="RTL">في بعض الأحيان تكون الفيروسات سببا للإصابة بالأمراض المعدية، ومثال على ذلك حالات العدوى الفيروسية التي تصيب الجيوب الأنفية والرئتين مثل حالات البرد والانفلونزا. إن المضادات الحيوية وتشمل ليفوكس، لا تقوم بقتل الفيروسات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدواء واستشر الطبيب المعالج إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك فرط تحسس لمادة ليفوفلوكساسين أو لأي من المضادات الحيوية من مجموعة الكوينولونات مثل موكسيفلوكساسين، سيبروفلوكساسين أو أوفلوكساسين أو لأي من مكونات أقراص ليفوكس (المذكورة في الفقرة رقم 6). وتكون علامات فرط التحسس على هيئة طفح جلدي، مشاكل في البلع أو التنفس، وتورم في الشفتين، الوجه، الحلق أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت قد أصبت سابقا بمرض الصرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشاكل بأوتار العضلات مثل التهاب الأوتار والمتعلقة باستخدام المضادات الحيوية التي تنتمي لمجموعة الكوينولونات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان المريض طفلا أو في مرحلة المراهقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت المريضة حامل أو من المحتمل أن تكون حاملا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت المريضة من الأمهات المرضعات.</p><p dir="RTL">يجب أن لا تتناول هذا الدواء إذا كانت تنطبق عليك أي من النقاط المذكورة أعلاه. تحدث مع الطبيب المعالج أو الصيدلي قبل تناول أقراص ليفوكس في حالة عدم التأكد إذا ما كانت هذه الشروط تنطبق عليك أم لا.</p><p dir="RTL">نظرا لاحتمالية حدوث التأثيرات الجانبية بشكل كبير في الأطفال والمراهقين أقل من 18 عام، لا يعطى ليفوكس لهذه الفئة من المرضى إلا في حالة الوقاية من مرض الجمرة الخبيثة وذلك في المرضى الذين يكون عمرهم 6 أشهر أو أكثر وتعرضوا لاستنشاق جرثومة الجمرة الخبيثة.</p><p dir="RTL"><strong>تحذير</strong>:</p><p dir="RTL"><strong>تمزق لأوتار أو تورم الوتر (التهاب الأوتار):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأوتار هي تلك الأحبال التي تربط العضلات بالعظام. قد تحدث آلام، تورم، تمزق والتهابات في الأوتار وتتضمن خلف الكاحل (وتر أخيليس)، الكتف، اليدين، والأماكن الأخرى التي تحتوي على أوتار وذلك في جميع الأعمار عند المرضى الذين يتناولون المضادات الحيوية من مجموعات الكوينولونات وتشمل ليفوكس. وتزداد خطورة حدوث هذه المشاكل في الأوتار إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عمرك أكثر من 60 عاما.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أدوية من مجموعة الستيرويدات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قمت بعملية نقل كلية، قلب، أو رئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدث لك تورم في الوتر (التهاب الوتر) وتمزق في الوتر عند تناولك أحد المضادات الحيوية من مجموعة الكوينولونات وكنت لا تعاني من أي عوامل الخطورة السابق ذكرها.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أسباب أخرى قد تؤدي إلى تمزق الوتر وتشمل:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيام بالتمارين والنشاط البدني.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل وظائف الكلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل سابقة في الوتر مثل تلك التي تحدث في مرضى التهاب المفاصل الروماتويدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب الاتصال بالطبيب المعالج في حالة ظهور أول علامات آلام الوتر، تورم الوتر أو التهاب الوتر. في هذه الحالة، يجب التوقف عن تناول ليفوكس حتى يتأكد الطبيب المعالج من أن هذه العلامات لا تتعلق بالتهاب الوتر أو تمزق الوتر. يجب أيضا تجنب القيام بالتمارين البدنية في المنطقة المتأثرة من الجسم. إن أكثر المناطق المتأثرة بحدوث الآلام والتمزق هي خلف الكاحل (وتر أخيليس). قد تحدث هذه التأثيرات في أوتار في أماكن أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب طلب المساعدة الطلبية في الحال في حالة حدوث أي من العلامات أو الأعراض التالية والتي قد تتعلق بتمزق الوتر مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سماع أو الإحساس بصكة أو طقطقة في منطقة الوتر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث كدمة مباشرة بعد الإصابة في منطقة الوتر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على القيام بتحريك المنطقة المصابة أو عدم تحمل الأوزان.</p><p dir="RTL"><strong>ب&zwnj;.&nbsp;&nbsp;&nbsp;&nbsp; الاحتياطات عند تناول ليفوكس:</strong></p><p dir="RTL"><strong>يجب التأكد من الطبيب أو الصيدلي قبل تناول هذا الدواء إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عمرك 60 عاما أو أكثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية من مجموعة الكورتيكوستيرويدات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدث لك من قبل نوبات عصبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشاكل في الأوتار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك نقص في بوتاسيوم الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدث لديك سابقا ضررا بالمخ جراء سكتة دماغية أو أي إصابة أخرى بالمخ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشاكل بالكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من نقص في إنزيم نازعة هيدروجين الجلوكوز -6-فسفات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدث لك من قبل مشاكل نفسية مرضية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدث لك من قبل مشاكل صحية بالقلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مريضا بالسكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك مشاكل متعلقة بالعظام والمفاصل مثل التهاب المفاصل الروماتويدي أو تاريخ مرضي آخر متعلق بمشاكل في المفاصل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشاكل في الأعصاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أو لدى أحد من أفراد عائلتك اضطرابات في دقات القلب وبخاصة حالة تسمى إطالة فترة QT في مخطط كهربية القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كانت لديك مشاكل في الكبد.</p><p dir="RTL">تحدث مع الطبيب المعالج أو الصيدلي قبل أن تتناول ليفوكس إذا لم تكن متأكدا من أن أي من الحالات السابقة متعلقة بك.</p><p dir="RTL"><strong>ج- التداخلات الدوائية من تناول هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية:</strong></p><p dir="RTL">أخبر الطبيب المعالج أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخرا أي أدوية أخرى. لا تبدأ بتناول أي علاج آخر جديد قبل أن تستشير الطبيب المعالج أو الصيدلي.</p><p dir="RTL">ويتضمن ذلك الأدوية التي قد يتم شراؤها بدون وصفة طبية وتشمل العلاج بالأعشاب. ويرجع ذلك إلى أن ليفوكس قد يؤثر على طريقة عمل بعض الأدوية الأخرى. بالإضافة إلى ذلك قد تقوم بعض الأدوية بالتأثير على طريقة عمل ليفوكس.</p><p dir="RTL">قم بإخبار الطبيب المعالج إذا كنت تتناول أي من الأدوية التالي ذكرها. وذلك نظرا لأن هذه الأدوية قد تزيد من فرصة حدوث الآثار الجانبية لديك إذا تم تناولها مع ليفوكس:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الكورتيكوستيرويدات</strong>: والتي تستخدم في علاج حالات الالتهاب. قد تزداد احتمالية اصابتك بالتهاب و /أو حدوث تمزق بالأوتار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>وارفرين</strong>: يستخدم كمضاد لتخثر الدم. قد تزداد القابلية للنزيف لديك. يجب على الطبيب المعالج القيام باختبارات معملية على الدم بصورة دورية وذلك لمعرفة مدى قدرة الدم على التخثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ثيوفيللين</strong>: يستخدم لمشاكل التنفس. قد تزداد لديك القابلية لحدوث نوبات عصبية عند تناوله مع ليفوكس.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية</strong>: وتستخدم في خالات الألم والالتهاب مثل الأسربين، إيبوبروفين، فينبيوفين، كيتوبروفين، وإندوميثاسين. قد تزداد لديك القابلية لحدوث نوبات عصبية عند تناوله مع ليفوكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سكلوسبورين</strong>: يستخدم بعد عمليات نقل الأعضاء. قد تزداد لديك فرصة حدوث الآثار الجانبية جراء تناول سكلوسبورين وذلك عند تناوله مع ليفوكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأدوية المعروفة بتأثيرها على ضربات قلبك</strong>: وتضمن الأدوية التي تستخدم في علاج خلل نظم القلب. مثل مضادات اضطراب النظم القلبي مثل الكينيدين، أميودارون.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب ثلاثية الحلقة</strong>: مثل أميتريبتيلين و إيميبرامين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>&nbsp;&nbsp; المضادات الحيوية من مجموعة الماكروليد</strong>: مثل إيريثرومايسن، أزيثرومايسين، وكلارثرومايسين.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات السكري التي يتم تناولها عن طريق الفم أو الأنسولين.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الذهان.</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدرات البول.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>بروبنسيد</strong>: (الذي يستخدم في علاج النقرس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سيميتيدين</strong>: والذي يستخدم في علاج قرحة الجهاز الهضمي وحرقة الفؤاد.</p><p dir="RTL">يجب توخي الحذر عند تناول أي من هذه العلاجات مع أقراص ليفوكس.</p><p dir="RTL">قد يضطر الطبيب المعالج لخفض الجرعة العلاجية من ليفوكس إذا كانت لديك مشاكل بالكلى.</p><p dir="RTL">لا تتناول أقراص ليفوكس في نفس الوقت مع الأدوية التالية. يجب تناول ليفوكس إما قبل ساعتين من تناول هذه الأدوية أو بعد ساعتين من تناول هذه الأدوية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الحديد (لعلاج الأنيميا)، العلاج بالفيتامينات المتعددة، أو المستحضرات الأخرى التي تحتوي على المغنيسيوم، الألومينيوم، الحديد الزنك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الحموضة التي تحتوي على المغنيسيوم أو الألومينوم (لعلاج الحموضة أو حرقة الفؤاد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكرلفات (لعلاج القرحة المعدية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديدانوسين مضاد للفيروسات يستخدم في علاج فيروس نقص المناعة البشرية.</p><p dir="RTL">هذا لأنها تؤثر على طريقة عمل ليفوكس.</p><p dir="RTL"><strong>اختبارات تحري الأفيونيات في البول:</strong></p><p dir="RTL">قد يؤدي استخدام ليفوكس أقراص لظهور نتائج إيجابية كاذبة لاختبارات تحري الأفيونيات في البول وهي مسكنات قوية للآلام. يجب أن تخبر الطبيب بأنك تتناول أقراص ليفوكس في حالة ما إذا طلب منك إجراء اختبار البول.</p><p dir="RTL"><strong>د- الحمل والرضاعة:</strong></p><p dir="RTL">لا تتناولي هذا الدواء إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت حاملا أو من المحتمل أن تكوني حاملا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تقومين بالرضاعة الطبيعية أو تخططين للقيام بالرضاعة الطبيعية.</p><p dir="RTL">اسألي الطبيب المعالج أو الصيدلي قبل تناول أي دواء إذا كنت حاملا أو تقومين بالرضاعة الطبيعية.</p><p dir="RTL"><strong>هـ- تأثير ليفوكس على القيادة واستخدام الآلات:</strong></p><p dir="RTL">قد تحدث لك بعض الآثار الجانبية عند تناول هذا الدواء مثل الإحساس بالدوخة، الرغبة في النوم، أو الإحساس بالدوار أو تغير في قدرتك على الإبصار. وقد تؤثر هذه الآثار الجانبية على قدرتك على التركيز وسرعة رد فعلك. وفي حالة حدوث هذه الأعراض لا تقم بالقيادة ولا تقم بأي أعمال تتطلب درجة عالية من الانتباه.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تناول أقراص ليفوكس حسب تعليمات الطبيب المعالج.</p><p dir="RTL">- يتم تناول هذا الدواء عن طريق الفم.</p><p dir="RTL">- يتم بلع الأقراص مع كمية مناسبة من الماء.</p><p dir="RTL">- يمكن تناول أقراص ليفوكس مع أو بدون تناول الطعام.</p><p dir="RTL">- سوف يقوم الطبيب المعالج بتحديد كمية أقراص ليفوكس التي يجب أن تتناولها.</p><p dir="RTL">- تعتمد الجرعة التي يتم تناولها على نوع العدوى البكتيرية الذي تعاني منه ومكان هذه العدوى.</p><p dir="RTL">- تعتمد فترة العلاج على مدى خطورة العدوى لديك.</p><p dir="RTL"><strong>المرضى من البالغين وكبار السن ذوي وظائف كلوية طبيعية:</strong></p><p dir="RTL"><strong>التهاب الجيوب الأنفية البكتيري الحاد:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 500 ملجم مرة واحدة يوميا لمدة 10-14 يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 750 ملجم مرة واحدة يوميا لمدة 5 أيام.</p><p dir="RTL"><strong>الالتهاب الرئوي:</strong></p><p dir="RTL"><strong>الالتهاب الرئوي المكتسب في المستشفى:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 750 ملجم مرة واحدة يوميا لمدة 7-14 يوم.</p><p dir="RTL"><strong>الالتهاب الرئوي المكتسب من المجتمع:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 500 ملجم مرة واحدة يوميا لمدة 10-14 يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 750 ملجم مرة واحدة يوميا لمدة 5 أيام.</p><p dir="RTL"><strong>الاشتداد الحاد لالتهاب القصبات المزمن:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 500 ملجم مرة واحدة يوميا لمدة 7 أيام.</p><p dir="RTL"><strong>عدوى السبيل البولي المصحوبة بمضاعفات أو التهاب الحويضة والكلية الحاد:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 750 ملجم مرة واحدة يوميا لمدة 5 أيام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 250 ملجم مرة واحدة يوميا لمدة 10 أيام.</p><p dir="RTL"><strong>عدوى السبيل البولي الغير مصحوبة بمضاعفات:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 250 ملجم مرة واحدة يوميا لمدة 3 أيام.</p><p dir="RTL"><strong>التهاب البروستاتا البكتيري المزمن:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 500 ملجم مرة واحدة يوميا لمدة 28 يوم.</p><p dir="RTL"><strong>التهاب الجلد والأنسجة تحت الجلد البكتيري المصحوب بمضاعفات:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 750 ملجم مرة واحدة يوميا لمدة 7-14 يوم.</p><p dir="RTL"><strong>التهاب الجلد والأنسجة تحت الجلد البكتيري الغير مصحوب بمضاعفات:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 500 ملجم مرة واحدة يوميا لمدة 7-10 أيام.</p><p dir="RTL"><strong>المرضى من البالغين الذين يعانون من مشاكل بالكلى:</strong></p><p dir="RTL">يجب على الطبيب المعالج تقليل الجرعة للمرضى الذين يعانون من مشاكل بالكلى.</p><p dir="RTL"><strong>المرضى من الأطفال والمراهقين:</strong></p><p dir="RTL">لا يوصف هذا الدواء للمرضى من الأطفال والمراهقين الذين يقل عمرهم عن 18 عاما.</p><p dir="RTL">إن الأطفال هم أكثر عرضة لحدوث مشاكل بالعظام، المفاصل أو الأوتار مثل الألم أو التورم وذلك عند تناول ليفوفلوكساسين.</p><p dir="RTL">إذا تم وصف ليفوكس لك بعد تعرضك للجمرة الخبيثة تكون الجرعة كالتالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 500 ملجم مرة واحدة يوميا لمدة 60 يوما وذلك في المرضى من البالغين والأطفال الذين يكون عمرهم 6 أشهر أو أكثر ويزيد وزنهم عن 50 كجم.</p><p dir="RTL">ويصرح باستخدام ليفوكس للتقليل من احتمالية الإصابة بالجمرة الخبيثة أو لتقليل احتمالية زيادة المرض سوءا وذلك عند تعرضك لجرثومة الجمرة الخبيثة.</p><p dir="RTL">يجب أن تتناول ليفوكس حسب تعليمات الطبيب المعالج. لا تتوقف عن تناول ليفوكس بدون استشارة الطبيب المعالج. إن التوقف عن تناول ليفوكس قبل نهاية المدة المحددة قديؤدي إلى تعرضك للإصابة بمرض الجمرة الخبيثة.</p><p dir="RTL">إن مدى أمان تناول ليفوكس لمدة تزيد عن 28 يوما في المرضى البالغين أو مدة تزيد عن 14 يوما في الأطفال الذين يكون عمرهم 6 أشهر أو أكثر ليس معروفا.</p><p dir="RTL">إذا كنت حاملا أو تخططين لحدوث حمل أثناء تناولك ليفوكس، فيجب أن تحددي مع الطبيب المعالج إذا ما كانت الفوائد المرجوة من تناول ليفوكس في حالة الجمرة الخبيثة أهم من المخاطر المحتملة.</p><p dir="RTL">في الأطفال الذين يكون عمرهم 6 أشهر أو أكثر وتعرضوا لاستنشاق جرثومة الجمرة الخبيثة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم ليفوكس لمنع حدوث مرض الجمرة الخبيثة (الجمرة الخبيثة الاستنشاقية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليس من المعروف مدى أمان تناول ليفوكس في الأطفال الذين يقل عمرهم عن 6 أشهر.</p><p dir="RTL"><strong>أ&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الزائدة من ليفوكس.</strong></p><p dir="RTL">إذا تناولت عددا من أقراص ليفوكس أكثر من الموصوف لك، استشر الطبيب المعالج أو الجأ إلى مساعدة طبية في الحال. خذ معك علبة الدواء لكي يتمكن الطبيب من معرفة الدواء الذي تناولته. قد تحدث بعض التأثيرات التالية: تشنجات أو نوبات عصبية، الإحساس بالارتباك، دوخة، نقص الوعي و الإدراك، ومشاكل في القلب تؤدي إلى اضطراب في ضربات القلب والإحساس بالغثيان.</p><p dir="RTL"><strong>ب&zwnj;-&nbsp;&nbsp;&nbsp;&nbsp; نسيان تناول جرعة ليفوكس:</strong></p><p dir="RTL">إذا نسيت تناول جرعة من أقراص ليفوكس، تناول الجرعة حالما تذكرت إلا إذا كان موعد الجرعة التي قد أوشك. في هذه الحالة، لا تتناول الجرعة مضاعفة.</p><p dir="RTL"><strong>ج- التوقف عن تناول ليفوكس:</strong></p><p dir="RTL">لا تتوقف عن تناول أقراص ليفوكس لمجرد الإحساس بتحسن حالتك، فمن المهم أن تتم مدة العلاج المحددة لك من قبل الطبيب المعالج.</p><p dir="RTL">إن التوقف عن تناول ليفوكس قبل نهاية المدة المحددة قد يؤدي إلى تعرضك للإصابة بالمرض مرة أخرى وقد تسوء حالتك أو قد تتكون للبكتيريا المسببة للمرض مناعة ضد العلاج.</p><p dir="RTL">إذا كانت لديك أي أسئلة أو استفسارات أخرى، استشر الطبيب المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية الأخرى، قد يسبب ليفوكس أعراض جانبية عند استخدامه، وبالرغم من ذلك ليس من الضروري أن تظهر هذه الأعراض في جميع المرضى الذين يستخدمون ليفوكس. وتكون معظم هذه الأعراض خفيفة إلى متوسطة وتختفي بعد فترة قصيرة.</p><p dir="RTL"><strong>توقف عن تناول ليفوكس وتوجه لزيارة الطبيب في الحال إذا ظهر عليك أي من الأعراض التالية:</strong></p><p dir="RTL"><strong>نادرة الحدوث جدا</strong> :( 10000 /1 &lt;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تفاعلات أرجية، حتى بعد تناول جرعة واحدة من العلاج. وقد تشمل العلامات حدوث طفح جلدي، مشاكل في البلع أو التنفس، شرى، بحة في الصوت، تسارع ضربات القلب، إغماء، وتورم في الشفتين، الوجه، الحلق، أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إحساس بالحرقان، وخز، ألم، ضعف وتنميل في الذراعين، اليدين، الأرجل أو الأقدام. قد تكون هذه علامات لما يسمى باعتلال الأعصاب. يجب اللجوء إلى الطبيب المعالج في الحال إذا ظهرت عليك أي من هذه الأعراض الجانبية.</p><p dir="RTL"><strong>نادرة الحدوث</strong> (1000 /1 &lt;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى جرثومية بالمعي (التهاب القولون الغشائي الكاذب):</p><p dir="RTL">إسهال مائي، إسهال مستمر أو مصحوبا بالدم، بالإضافة إلى تقلص بالمعدة وارتفاع درجة الحرارة. قد تكون هذه علامات لمشاكل خطيرة بالأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم والتهاب بالأوتار. ويعتبر وتر أخيليس الأكثر تعرضا لهذه الحالة وقد يتعرض الوتر في بعض الأحيان إلى تمزق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات عصبية (تشنجات).</p><p dir="RTL"><strong>أخرى</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شديد الخطورة ويشمل تكون حويصلات، تقشر بالجلد حول الشفتين، العين، الفم، الأنف، والأعضاء التناسلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، تغير لون الجلد والعينين إلى اللون الأصفر، تحول لون البول إلى اللون الداكن، حكة، أو ألم بالمعدة (البطن). قد تكون هذه علامات لمشاكل في الكبد.</p><p dir="RTL"><strong>استشر الطبيب المعالج إذا زادت الأعراض الجانبية التالية سوءا أو إذا استمرت لعدة أيام:</strong></p><p dir="RTL"><strong>شائعة </strong>( 10 /1 &lt;):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان وإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيمات الكبد في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أرق.</p><p dir="RTL"><strong>غير شائعة</strong> ( 100 /1 &lt;):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة، وطفح جلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، اضطرابات بالمعدة (عسر هضم)، قيء أو ألم في منطقة المعدة، انتفاخ أو إمساك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار، الإحساس بالنعاس، اضطرابات في النوم أو الإحساس بالعصبية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف عام.</p><p dir="RTL"><strong>نادرة الحدوث</strong> ( 1000 /1 &lt;):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإحساس بالنخز في اليدين والأرجل (مذل) أو رعشة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق، اكتئاب، مشاكل نفسية، هياج أو اضطراب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع في ضربات القلب بصورة غير اعتيادية أو انخفاض في ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام بالمفاصل أو العضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات وسهولة النزف والتر ترجع إلى نقص في الصفائح الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في عدد خلايا الدم البيضاء (يسمى قلة العدلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة أو أزيز أثناء التنفس (تشنج قصبي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث حكة بصورة شديدة أو شرى.</p><p dir="RTL"><strong>نادرة الحدوث ج</strong>دا ( 10000 /1 &lt;):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة تحسس الجلد لأشعة الشمس وللأشعة فوق البنفسجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في مستوى السكر بالدم وارتفاع مستوى السكر بالدم. إن هذه الأعراض مهمة لمرضى السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في السمع أو الإبصار أو تغير في حاستي التذوق والشم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو سمع أشياء غير موجودة (هلاوس)، تغير في الرأي أو طريقة التفكير (تفاعلات نفسية) مع وجود فرصة لحدوث أفكار انتحارية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل بالدورة الدموية (صدمة شبيهة بالتأقية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وهن بالعضلات. ويعتبر هذا العرض مهما في حالة المرضى المصابين بمرض الوهن العضلي الوبيل وهو مرض نادر يصيب الجهاز العصبي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بالكبد، خلل في وضيفة الكلى وفي بعض الأحيان فشل كلوي والذي قد يكون بسبب تفاعل أرجي بالكلى يسمى التهاب الكلية الخلالي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى، التهاب الحلق، وشعور عام بالاعتلال بصورة مستمرة ولا تختفي. قد يكون ذلك بسبب انخفاض عدد خلايا الدم البيضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى وتفاعلات أرجية بالرئة.</p><p dir="RTL"><strong>أعراض جانبية أخرى تشمل:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم الحمراء (أنيميا). وقد تؤدي هذه الحالة إلى تغير لون الجلد إلى اللون الشاحب أو الأصفر وذلك بسبب الضرر الذي يصيب خلايا الدم الحمراء وانخفاض عدد جميع خلايا الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الاستجابة المناعية (فرط التحسس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط التعرق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام وتشمل آلام بالظهر والصدر والأطراف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الحركة والمشي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات البرفيرية في المرضى الذين يعانون من مرض البرفيرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الأوعية الدموية بسبب تفاعلات أرجية.</p><p dir="RTL">استشر الطبيب المعالج أو الصيدلي إذا زادت الأعراض الجانبية سوءا أو إذا لاحظت أي أعراض جانبية أخرى غير مذكورة بهذه النشرة الطبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-يحفظ بعيدا عن متناول الأطفال.</p><p dir="RTL">-يحفظ في درجة حرارة تقل عن 30 درجة مئوية في عبوته الأصلية.</p><p dir="RTL">-لا تستخدم ليفوكس بعد انتهاء تاريخ الصلاحية المدون على العبوة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة ليفوفلوكساسين. يحتوي كل قرص من ليفوكس 250 ملجم أقراص على 250 ملجم من مادة فلوكساسين، يحتوي كل قرص من ليفوكس على 500 ملجم أقراص على 500 ملجم من مادة ليفوفلوكساسين، يحتوي كل قرص من ليفوكس على 750 ملجم أقراص على 750 ملجم من مادة ليفوفلوكساسين.</p><p dir="RTL">المواد الغير فعالة بالقرص: هيدروكسي بروبايل ميثير سيلليلوز، كروسبوفيدون، مايكروكريستالين سيسلليلوز مضاف إليها السيليكا، ستيارات المغنيسيوم.</p><p dir="RTL">الطبقة المغلفة: بولي سوربات 80، ثاني أكسيد التيتانيوم، تالك نقي، بولي إيثيلين جليكول، هيدروكسي بروبايل ميثيل سيلليلوز، أكسيد الحديد الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">أقراص ليفوكس هي أقراص مغلفة بطبقة رقيقة للتناول عن طريق الفم وهي أقراص مستطيلة لونها أصفر فاتح.</p><p dir="RTL" style="text-align:right">يتوفر ليفوكس 250، 500، 750 ملجم في عبوات تحتوي على 5 أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>انتاج الدوائية</strong></p><p dir="RTL">مصنع الأدوية بالقصيم،</p><p dir="RTL">المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم الموافقة على هذه النشرة بتاريخ: يونيو 2011. 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levox 250 mg film-coated tablets
Levox 500 mg film-coated tablets
Levox 750 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 250,500 & 750 mg of levofloxacin 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets
Levox 250mg  - A yellow, oblong, biconvex film-coated tablet engraved with "210" on one side and plain surface on the other side.
Levox 500mg - A yellow, oblong, biconvex film-coated tablet engraved with "211" on one side and plain surface on the other side.
Levox 750mg - A yellow, oblong, biconvex film-coated tablet engraved with "212" on one side and plain surface on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levox tablets are indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1):</p><p>&bull; Acute bacterial sinusitis</p><p>&bull; Acute exacerbations of chronic bronchitis</p><p>&bull; Community-acquired pneumonia</p><p>&bull; Complicated skin and soft tissue infections</p><p>For the above-mentioned infections Levox tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.</p><p>&bull; Pyelonephritis and complicated urinary tract infections (see section 4.4)</p><p>&bull; Chronic bacterial prostatitis</p><p>&bull; Uncomplicated cystitis (see section 4.4)</p><p>&bull; Inhalation Anthrax: postexposure prophylaxis and curative treatment (see section 4.4)</p><p>Levox tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levox tablets are administered once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.</p><p>Levox tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin; given the bioequivalence of the parenteral and oral forms, the same dosage can be used.</p><p><u>Posology</u></p><p>The following dose recommendations can be given for Levofloxacin:</p><p><strong><em>Dosage in patients with normal renal function</em></strong><strong>&nbsp;</strong>(creatinine clearance &gt; 50 ml/min)</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose regimen</strong></p><p><strong><em>(according to severity)</em></strong></p></td><td style="vertical-align:top"><p><strong>Duration of treatment</strong></p><p><strong><em>(according to severity)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial sinusitis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>10 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial exacerbations of chronic bronchitis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>7 - 10 days</p></td></tr><tr><td style="vertical-align:top"><p>Community-acquired pneumonia</p></td><td style="vertical-align:top"><p>500 mg once or twice daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>7 &ndash; 10 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated cystitis</p></td><td style="vertical-align:top"><p>250 mg once daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td style="vertical-align:top"><p>Chronic bacterial prostatitis.</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>28 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>500 mg once or twice daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Inhalation Anthrax</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>8 weeks</p></td></tr></tbody></table><p><em><u>Special populations</u></em></p><p><strong><em>Renal impairment&nbsp;</em></strong>(creatinine clearance &le;50 ml/min)</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top">&nbsp;</td><td colspan="3" style="vertical-align:top"><p><strong>Dose regimen</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>250 mg/24 h</strong></p></td><td style="vertical-align:top"><p><strong>500 mg/24 h</strong></p></td><td style="vertical-align:top"><p><strong>500 mg/12 h</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Creatinine clearance</strong></p></td><td style="vertical-align:top"><p><em>first dose:</em>&nbsp;250 mg</p></td><td style="vertical-align:top"><p><em>first dose:</em>&nbsp;500 mg</p></td><td style="vertical-align:top"><p><em>first dose:</em>&nbsp;500 mg</p></td></tr><tr><td style="vertical-align:top"><p>50-20 ml/min</p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/24 h</p></td><td style="vertical-align:top"><p><em>then</em>&nbsp;: 250 mg/24 h</p></td><td style="vertical-align:top"><p><em>then</em>&nbsp;: 250 mg/12 h</p></td></tr><tr><td style="vertical-align:top"><p>19-10 ml/min</p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/48 h</p></td><td style="vertical-align:top"><p><em>then</em>&nbsp;: 125 mg/ 24 h</p></td><td style="vertical-align:top"><p><em>then</em>&nbsp;: 125 mg/12 h</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10 ml/min</p><p>(including haemodialysis and CAPD)&nbsp;<sup>1</sup></p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/48 h</p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/24 h</p></td><td style="vertical-align:top"><p><em>then:</em>&nbsp;125 mg/24 h</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).</p><p><strong><em>Hepatic impairment</em></strong></p><p>No adjustment of dosage is required since levofloxacin is not metabolised to any relevant extent by the liver and is mainly excreted by the kidneys.</p><p><strong><em>Elderly</em></strong></p><p>No adjustment of dose is required in the elderly, other than that imposed by consideration of renal function (see section 4.4 &ldquo;Tendintis and tendon rupture&rdquo; and &ldquo;QT interval prolongation&rdquo;).</p><p><strong><em>Paediatric population</em></strong></p><p>Levofloxacin is contraindicated in children and growing adolescents (see section 4.3).</p><p><strong><em>Method of administration</em></strong></p><p>For oral use.</p><p>Levox tablets should be swallowed without crushing and with sufficient amount of liquid. They may be divided at the score line to adapt the dose. The tablets may be taken during meals or between meals. Levox tablets should be taken at least two hours before or after iron salts, zinc salts, magnesium- or aluminium-containing antacids, or didanosine (<em>only didanosine formulations with aluminium or magnesium containing buffering agents</em>), and sucralfate administration, since reduction of absorption can occur (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levox tablets must not be used:
• in patients hypersensitive to the active substance or other quinolones or to any of the excipients listed in section 6.1,
• in patients with epilepsy,
• in patients with history of tendon disorders related to fluoroquinolone administration,
• in children or growing adolescents,
• during pregnancy,
• in breast-feeding women.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.</p><p>&nbsp;</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, Behcet`s disease, hypertension, known atherosclerosis).</p><p>&nbsp;</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p><strong>&nbsp;</strong></p><p>Methicillin resistant<em>&nbsp;S. aureus</em>&nbsp;are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).</p><p>Levofloxacin may be used in the treatment of Acute Bacterial Sinusitis and Acute Exacerbation of Chronic Bronchitis when these infections have been adequately diagnosed.</p><p>Resistance to fluoroquinolones of&nbsp;<em>E. coli</em>&nbsp;&ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in&nbsp;<em>E. coli</em>&nbsp;to fluoroquinolones.</p><p>Inhalation Anthrax: Use in humans is based on&nbsp;<em>in vitro Bacillus anthracis</em>&nbsp;susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p><strong><em>Tendinitis and tendon rupture</em></strong></p><p>Tendinitis may rarely occur. It most frequently involves the Achilles tendon and may lead to tendon rupture. Tendinitis and tendon rupture, sometimes bilateral, may occur within 48 hours of starting treatment with levofloxacin and have been reported up to several months after discontinuation of treatment. The risk of tendinitis and tendon rupture is increased in patients aged over 60 years, in patients receiving daily doses of 1000 mg and in patients using corticosteroids. The daily dose should be adjusted in elderly patients based on creatinine clearance (see section 4.2). Close monitoring of these patients is therefore necessary if they are prescribed levofloxacin. All patients should consult their physician if they experience symptoms of tendinitis. If tendinitis is suspected, treatment with levofloxacin must be halted immediately, and appropriate treatment (e.g. immobilisation) must be initiated for the affected tendon (see sections 4.3 and 4.8).</p><p><strong><em>Clostridium difficile-associated disease</em></strong></p><p>Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of&nbsp;<em>Clostridium difficile</em>-associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudomembranous colitis (see section 4.8). It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, levofloxacin should be stopped immediately and appropriate treatment initiated without delay. Anti-peristaltic medicinal products are contraindicated in this clinical situation..</p><p><strong><em>Patients predisposed to seizures</em></strong></p><p>Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures or concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline (see section 4.5). In case of convulsive seizures (see section 4.8), treatment with levofloxacin should be discontinued.</p><p><strong><em>Patients with G-6- phosphate dehydrogenase deficiency</em></strong></p><p>Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.</p><p><strong><em>Patients with renal impairment</em></strong></p><p>Since levofloxacin is excreted mainly by the kidneys, the dose of Levofloxacin should be adjusted in patients with renal impairment (see section 4.2).</p><p><strong><em>Hypersensitivity reactions</em></strong></p><p>Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should discontinue treatment immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.</p><p><strong><em>Severe bullous reactions</em></strong></p><p>Cases of severe bullous skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with levofloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.</p><p><strong><em>Dysglycaemia</em></strong></p><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g., glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended see section 4.8).</p><p><strong><em>Prevention of photosensitisation</em></strong></p><p>Photosensitisation has been reported with levofloxacin (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g. sunray lamp, solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.</p><p><strong><em>Patients treated with Vitamin K antagonists</em></strong></p><p>Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomitantly (see section 4.5).</p><p><strong><em>Psychotic reactions</em></strong></p><p>Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour- sometimes after only a single dose of levofloxacin (see section 4.8). In the event that the patient develops these reactions, levofloxacin should be discontinued and appropriate measures instituted. Caution is recommended if levofloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p><strong><em>QT interval prolongation</em></strong></p><p>Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>- congenital long QT syndrome</p><p>- concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics)</p><p>- uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)</p><p>- cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations.</p><p>(see sections 4.2&nbsp;<em>Elderly</em>, 4.5, 4.8, and 4.9).</p><p><strong><em>Peripheral neuropathy</em></strong></p><p>Peripheral sensory neuropathy and peripheral sensory motor neuropathy have been reported in patients receiving fluoroquinolones, including levofloxacin, which can be rapid in its onset (see section 4.8). Levofloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.</p><p><strong><em>Hepatobiliary disorders</em></strong></p><p>Cases of hepatic necrosis up to fatal hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis (see section 4.8). Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.</p><p><strong><em>Exacerbation of myasthenia gravis</em></strong></p><p>Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.</p><p><strong><em>Vision disorders</em></strong></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p><strong><em>Superinfection</em></strong></p><p>The use of levofloxacin, especially if prolonged, may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.</p><p><strong><em>Interference with laboratory tests</em></strong></p><p>In patients treated with levofloxacin, determination of opiates in urine may give false-positive results. It may be necessary to confirm positive opiate screens by more specific method.</p><p>Levofloxacin may inhibit the growth of&nbsp;<em>Mycobacterium tuberculosis</em>&nbsp;and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effect of other medicinal products on levofloxacin</strong></p><p><strong><em>Iron salts, zinc salts, magnesium- or aluminium-containing antacids, didanosine</em></strong></p><p>Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminium-containing antacids, or didanosine (<em>only didanosine formulations with aluminium or magnesium containing buffering agents</em>) are administered concomitantly with Levox tablets. Concurrent administration of fluoroquinolones with multi-vitamins containing zinc appears to reduce their oral absorption. It is recommended that preparations containing divalent or trivalent cations such as iron salts, zinc salts or magnesium- or aluminium-containing antacids, or didanosine (<em>only didanosine formulations with aluminium or magnesium containing buffering agents</em>) should not be taken 2 hours before or after levofloxacin administration (see section 4.2). Calcium salts have a minimal effect on the oral absorption of levofloxacin.</p><p><strong><em>Sucralfate</em></strong></p><p>The bioavailability of Levox tablets is significantly reduced when administered together with sucralfate. If the patient is to receive both sucralfate and Levofloxacin, it is best to administer sucralfate 2 hours after the levofloxacin tablet administration (see section 4.2).</p><p><strong><em>Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs</em></strong></p><p>No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold.</p><p>Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.</p><p><strong><em>Probenecid and cimetidine</em></strong></p><p>Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance.</p><p>Caution should be exercised when levofloxacin is co-administered with drugs that affect the tubular renal secretion such as probenecid and cimetidine, especially in renally impaired patients.</p><p><strong><em>Other relevant information</em></strong></p><p>Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.</p><p><strong>Effect of Levofloxacin on other medicinal products</strong></p><p><strong><em>Ciclosporin</em></strong></p><p>The half-life of ciclosporin was increased by 33% when co-administered with levofloxacin.</p><p><strong><em>Vitamin K antagonists</em></strong></p><p>Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4).</p><p><strong><em>Drugs known to prolong QT interval</em></strong></p><p>Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4 QT interval prolongation).</p><p><strong><em>Other relevant information</em></strong></p><p>In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.</p><p><strong>Other forms of interactions</strong></p><p><strong><em>Food</em></strong></p><p>There is no clinically relevant interaction with food. Levox tablets may therefore be administered regardless of food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong></p><p>There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). However, in the absence of human data and due to the experimental data that suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women (see sections 4.3 and 5.3).</p><p><strong><em>Breast-feeding</em></strong></p><p>Levofloxacin is contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk; however other fluoroquinolones are excreted in breast milk. In the absence of human data and due to the experimental data that suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in breast-feeding women (see sections 4.3 and 5.3).</p><p><strong><em>Fertility</em></strong></p><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient&#39;s ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information given below is based on data from clinical studies in more than 8300 patients and on extensive post marketing experience.</p><p>Frequencies are defined using the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common (&ge;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (&ge;1/1,000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare (&ge;1/10,000 to &lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Not known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Fungal infection including Candida infection</p><p>Pathogen resistance</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Eosinophilia</p><p>Leukopenia</p></td><td style="vertical-align:top"><p>Neutropenia, Thrombocytopenia</p></td><td style="vertical-align:top"><p>Haemolytic anaemia, Pancytopenia</p><p>Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Angioedema</p><p>Hypersensitivity (see section 4.4)</p></td><td style="vertical-align:top"><p>Anaphylactic shock<sup>a</sup></p><p>Anaphylactoid shock<sup>a</sup>(see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Hypoglycaemia, particularly in diabetic patients (see section 4.4)</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p><p>Hypoglycaemic coma (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Confusional state</p><p>Anxiety</p><p>Nervousness</p></td><td style="vertical-align:top"><p>Psychotic reactions (with e.g. hallucination, paranoia)</p><p>Depression</p><p>Agitation</p><p>Abnormal dreams</p><p>Nightmares</p></td><td style="vertical-align:top"><p>Psychotic disorders with self-endangering behaviour including suicidal ideation or suicide attempt</p><p>(see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Somnolence</p><p>Tremor</p><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Convulsion (see section 4.3 and 4.4)</p><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Peripheral sensory neuropathy (see section 4.4)</p><p>Peripheral sensory motor neuropathy (see section 4.4)</p><p>Parosmia including anosmia</p><p>Dyskinesia</p><p>Extrapyramidal disorder</p><p>Ageusia</p><p>Syncope</p><p>Benign intracranial hypertension</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Visual disturbances such as blurred vision (see section 4.4)</p></td><td style="vertical-align:top"><p>Transient vision loss (see section 4.4), uveitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and Labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>Hearing loss</p><p>Hearing impaired</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia</p><p>Palpitation</p></td><td style="vertical-align:top"><p>Ventricular tachycardia, which may result in cardiac arrest</p><p>Ventricular arrhythmia and torsades de pointes (reported predominantly in patients with risk factors for QT prolongation), Electrocardiogram QT prolonged (see section 4.4 and 4.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Bronchospasm</p><p>Pneumonitis</p><p>allergic</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>Vomiting</p><p>Nausea</p></td><td style="vertical-align:top"><p>Abdominal pain</p><p>Dyspepsia</p><p>Flatulence</p><p>Constipation</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhoea-haemorrhagic which in very rare cases may be indicative of enterocolitis, including pseudomembranous colitis (see section 4.4)</p><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Hepatic enzyme increased (ALT/AST, alkaline phosphatase, GGT)</p></td><td style="vertical-align:top"><p>Blood bilirubin increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Jaundice and severe liver injury, including cases with fatal acute liver failure, primarily in patients with severe underlying diseases (see section 4.4)</p><p>Hepatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong><sup>b</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p><p>Urticaria</p><p>Hyperhidrosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p><p>Stevens-Johnson syndrome</p><p>Erythema multiforme</p><p>Photosensitivity reaction (see section 4.4)</p><p>Leukocytoclastic vasculitis</p><p>Stomatitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Arthralgia</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Tendon disorder (see sections 4.3 and 4.4) including tendinitis (e.g. Achilles tendon)</p><p>Muscular weakness which may be of special importance in patients with myasthenia gravis (see section 4.4)</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p><p>Tendon rupture (e.g. Achilles tendon) (see sections 4.3 and 4.4)</p><p>Ligament rupture</p><p>Muscle rupture</p><p>Arthritis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Renal failure acute (e.g. due to interstitial nephritis)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Pain (including pain in back, chest, and extremities)</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose</p><p><sup>b</sup>&nbsp;Mucocutaneous reactions may sometimes occur even after the first dose</p><p>Other undesirable effects which have been associated with fluoroquinolone administration include:</p><p>&bull; attacks of porphyria in patients with porphyria</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_3" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:22.65pt;margin-top:4.65pt;
 width:377.2pt;height:119.25pt;z-index:251658240;visibility:visible;
 mso-width-relative:margin;mso-height-relative:margin' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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"/><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Reporting hotline: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdose of Levox tablets are central nervous system symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions.</p><p>CNS effects including confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Antacids may be used for protection of gastric mucosa. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body. No specific antidote exists.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones, ATC code: J01 MA12</p><p>Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S (-) enantiomer of the racemic active substance ofloxacin.</p><p><u>Mechanism of action</u></p><p>As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex and topoisomerase IV.</p><p><u>PK/PD relationship</u></p><p>The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum C<sub>max&nbsp;</sub>or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).</p><p><strong><em>Mechanism of resistance</em></strong></p><p>Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common in&nbsp;<em>Pseudomonas aeruginosa</em>) and efflux mechanisms may also affect susceptibility to levofloxacin.</p><p><u>Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents</u>.</p><p><strong><em>Breakpoints</em></strong></p><p>The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/L).</p><p><strong><em>EUCAST clinical MIC breakpoints for levofloxacin (version 2.0, 2012-01-01):</em></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Pathogen</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriacae</p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas spp.</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter spp.</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus spp.</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>S.pneumoniae&nbsp;<sup>1</sup></em></p></td><td style="vertical-align:top"><p>&le;2 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus A,B,C,G</em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>H.influenzae&nbsp;<sup>2,3</sup></em></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>M.catarrhalis</em><sup>3</sup></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Non-species related breakpoints<sup>4</sup></p></td><td style="vertical-align:top"><p>&le;1 mg/L</p></td><td style="vertical-align:top"><p>&gt;2 mg/L</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup>&nbsp;The breakpoints for levofloxacin relate to high dose therapy.</p><p><sup>2</sup>&nbsp;Low-level fluoroquinolone resistance (ciprofloxacin MICs of 0.12-0.5 mg/l) may occur but there is no evidence that this resistance is of clinical importance in respiratory tract infections with&nbsp;<em>H. influenzae</em>.</p><p><sup>3</sup>&nbsp;Strains with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate must be sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant.</p><p><sup>4</sup>&nbsp;Breakpoints apply to an oral dose of 500 mg x 1 to 500 mg x 2 and an intravenous dose of 500 mg x 1 to 500 mg x 2.</p></td></tr></tbody></table><p>The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Commonly susceptible species</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive bacteria</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacillus anthracis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus&nbsp;</em>methicillin-susceptible</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus saprophyticus</em></p></td></tr><tr><td style="vertical-align:top"><p>Streptococci, group C and G</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus agalactiae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative bacteria</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Eikenella corrodens</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus para-influenzae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Klebsiella oxytoca</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Pasteurella multocida</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Proteus vulgaris</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Providencia rettgeri</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic bacteria:</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Peptostreptococcus</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other</u></p></td></tr><tr><td style="vertical-align:top"><p>Chlamydophila<em>&nbsp;pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p>Chlamydophila<em>&nbsp;psittaci</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Chlamydia trachomatis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>LEGIONELLA PNEUMOPHILA</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Mycoplasma pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Mycoplasma hominis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Ureaplasma urealyticum</em></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Species for which acquired resistance may be a problem</u></strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive bacteria</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus faecalis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus&nbsp;</em>methicillin-resistant<sup>#</sup></p></td></tr><tr><td style="vertical-align:top"><p>Coagulase negative&nbsp;<em>Staphylococcus spp</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative bacteria</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter baumannii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Citrobacter freundii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacter aerogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacter cloacae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Escherichia coli</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Klebsiella pneumoniae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Morganella morganii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Proteus mirabilis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Providencia stuartii</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Serratia marcescens</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic bacteria:</u></p></td></tr><tr><td style="vertical-align:top"><p><em>Bacteroides fragilis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Inherent Resistant Strains</u></p></td></tr><tr><td style="vertical-align:top"><p><strong><em><u>Aerobics Gram-positive bacteria</u></em></strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus faecium</em></p></td></tr></tbody></table><p><sup>#</sup>&nbsp;Methicillin-resistant&nbsp;<em>S.aureus&nbsp;</em>are very likely to possess co-resistance to fluoroquinolones, including levofloxcacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1-2 h. The absolute bioavailability is approximately 99-100 %.</p><p>Food has little effect on the absorption of levofloxacin.</p><p>Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.</p><p><u>Distribution</u></p><p>Approximately 30 - 40 % of levofloxacin is bound to serum protein.</p><p>The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues.</p><p><u>Penetration into tissues and body fluids</u></p><p>Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration into cerebro-spinal fluid.</p><p><u>Biotransformation</u></p><p>Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for &lt; 5 % of the dose excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.</p><p><u>Elimination</u></p><p>Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma (t<sub>&frac12;</sub>: 6 - 8 h). Excretion is primarily by the renal route (&gt; 85 % of the administered dose).</p><p>The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/-29.2 ml/min.</p><p>There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.</p><p><u>Linearity</u></p><p>Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.</p><p><u>Special populations</u></p><p><em>Renal impairment</em></p><p>The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal function renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:</p><p>Pharmacokinetics in renal insufficiency following single oral 500 mg dose</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Cl<sub>cr</sub>&nbsp;[ml/min]</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>20 - 49</p></td><td style="vertical-align:top"><p>50 - 80</p></td></tr><tr><td style="vertical-align:top"><p>Cl<sub>R</sub>&nbsp;[ml/min]</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>57</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub>&nbsp;[h]</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>9</p></td></tr></tbody></table><p><strong><em>Elderly</em></strong></p><p><u>There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects, except those associated with differences in creatinine clearance.</u></p><p><u>Gender differences</u></p><p>Separate analysis for male and female subjects showed small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.</p><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on foetuses was delayed maturation as a result of maternal toxicity.</p><p>Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells&nbsp;<em>in vitro</em>. These effects can be attributed to inhibition of topoisomerase II.&nbsp;<em>In vivo</em>&nbsp;tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.</p><p>Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenicity study.</p><p>In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Active Ingredient:</strong></p><p>Levofloxacin Hemihydrate equivalent to 250, 500 &amp; 750 Levofloxacin</p><p><strong>&nbsp;</strong></p><p><strong>Excipients for Core:</strong></p><p>Hydroxypropyl Methylcellulose EP</p><p>Crospovidone NF</p><p>Silicified Microcrystalline Cellulose (Prosolv <strong>SMCC</strong> 50)</p><p>Magnesium Stearate</p><p><strong>&nbsp;</strong></p><p><strong>Excipients for Film Coating:</strong></p><p>Polysorbate 80 EP</p><p>Titanium Dioxide EP</p><p>Purified Talc EP</p><p>Polyethylene Glycol MW 6000 EP</p><p>Hydroxypropyl Methylcellulose EP</p><p>Iron Oxide Yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                For Levox 250 mg: 2 Years.
For Levox 500 & 750 mg: 36 months (3 years).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister Pack</p><p>Lidding material: Aluminum Foil</p><p>Forming Film: PVC/PE/PVDC</p><p>(PVC: polyvinyl chloride, PE: polyethylene, PVDC polyvinylidene chloride)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by SPIMACO
Al Qassim pharmaceutical Plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
Saudi Arabia 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                February 2022.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>